New drug AB821 enters first human tests for advanced melanoma

NCT ID NCT07027488

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new drug called AB821 in 50 adults with advanced melanoma or other solid tumors that respond to immune therapies. The main goal is to check safety and find the right dose. Participants receive AB821 by IV every 2 or 3 weeks for up to two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

AB821 (a drug given by IV infusion)

What this could lead to

If it works, this could point toward a new treatment option for advanced melanoma and other immune-responsive solid tumors.

What could go wrong

This is a very early Phase 1 trial with only 50 participants, so it is primarily testing safety. The drug may not shrink tumors or may cause serious side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous melanoma cutaneous neuroendocrine carcinoma head and neck squamous cell carcinoma melanoma metastatic melanoma non-small cell lung carcinoma renal cell carcinoma urinary bladder carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Yale University

    RECRUITING

    New Haven, Connecticut, 06510, United States

    Contact Email: •••••@•••••